Phase 2 trial with CCX354 showed clinical benefit in RA patients. CCX721 reduced tumor growth in murine 5TGM1 MM model. CCX9588 reduced OPM2 or RPMI-8226 dissemination in intratibial xenograft models of MM. Co-administration of CCX9588 with an anti-PDL1 antibody reduces tumor burden in a breast cancer mouse model. The gene discussed is CD274; the disease is Miyoshi myopathy.